|
|
|
|
|
26.03.26 - 13:33
|
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt (GlobeNewswire EN)
|
|
|
Nes-Ziona, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today reported that the Rain Foundation, which independently oversees the decentralized prediction markets Rain protocol, announced the launch of its AI agent-ready interface and a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction market platforms through AI agents, including OpenClaw....
|
|
|
|
|
|
|
24.03.26 - 13:33
|
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program (GlobeNewswire EN)
|
|
|
Nes-Ziona, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company, today announced the consummation of a $21 million debt financing agreement with The Lind Partners, a New York based institutional fund manager (“Lind”), which provided the Company with net proceeds of approximately $18.7 million before deducting offering expenses. The transaction closed on March 23, 2026. The note is convertible into Enlivex's ordinary shares at a fixed conversion price of $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2025....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.09.25 - 14:18
|
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex′s Knee Osteoarthritis Program (GlobeNewswire EN)
|
|
|
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal disease, alongside Enlivex's Vice Chairman and D. Boral's Research Director. The September 30 KOL webinar will explore recent breakthroughs in treatment approaches discussing the positive Phase IIa topline data from Enlivex's Allocetra™ program in moderate-to-severe knee osteoarthritis (KOA) patients. Data demonstrated clinically meaningful and highly statistically significant reduction in pain and improvements in function in idiopathic, age-related knee osteoarthritis patients, a large, unders...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
